{"acquisitions":[],"changes":[],"country":"BE","description":"Clinical-stage biotech developing selective HDAC6 inhibitors for neuromuscular, neurodegenerative and cardio-metabolic disease. Patients with Charcot-Marie-Tooth, ALS and related conditions are the initial focus. A novel non-hydroxamate, non-hydrazide chemotype preserves HDAC6's beneficial functions, making it suited to chronic dosing.","domain":"augustinetherapeutics.com","employees":null,"founded":2018,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":50.879202,"lng":4.701168,"location":"Leuven","multiples":[],"name":"Augustine Therapeutics","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":91800000,"connectionsAmong":[],"currency":"EUR","date":"2025-06-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"augustinetherapeutics-com-2025-06-01-series-a","source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-02","status":"attributed","url":null},"status":"attributed","type":"series-a","url":null}],"slug":"augustinetherapeutics-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-02","status":"attributed","url":null},{"fact":"existence","publisher":"augustinetherapeutics.com","retrievedAt":"2026-05-02","status":"self-reported","url":"https://augustinetherapeutics.com"},{"fact":"description","publisher":"augustinetherapeutics.com","retrievedAt":"2026-05-02","status":"self-reported","url":"https://augustinetherapeutics.com"}],"stage":"series-a","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":[],"totalRaisedUsd":108000000,"traction":[],"updatedAt":"2026-05-02","valuations":[]}